Follow
Vidyalakshmi Sethunath
Vidyalakshmi Sethunath
Scientist, Foundation Medicine., Inc.
Verified email at foundationmedicine.com
Title
Cited by
Cited by
Year
Towards personalized treatment for early stage HER2-positive breast cancer
K Goutsouliak, J Veeraraghavan, V Sethunath, C De Angelis, CK Osborne, ...
Nature Reviews Clinical Oncology 17 (4), 233-250, 2020
2252020
FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer
X Fu, R Pereira, C De Angelis, J Veeraraghavan, S Nanda, L Qin, ...
Proceedings of the National Academy of Sciences 116 (52), 26823-26834, 2019
1232019
HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer
X Xu, C De Angelis, KA Burke, A Nardone, H Hu, L Qin, J Veeraraghavan, ...
Clinical Cancer Research 23 (17), 5123-5134, 2017
1102017
Activation of the IFN signaling pathway is associated with resistance to CDK4/6 inhibitors and immune checkpoint activation in ER-positive breast cancer
C De Angelis, X Fu, ML Cataldo, A Nardone, R Pereira, J Veeraraghavan, ...
Clinical Cancer Research 27 (17), 4870-4882, 2021
59*2021
Integrative clinical and molecular characterization of translocation renal cell carcinoma
Z Bakouny, A Sadagopan, P Ravi, NY Metaferia, J Li, S AbuHammad, ...
Cell reports 38 (1), 2022
532022
Targeting the mevalonate pathway to overcome acquired anti-HER2 treatment resistance in breast cancer
V Sethunath, H Hu, C De Angelis, J Veeraraghavan, L Qin, N Wang, ...
Molecular Cancer Research 17 (11), 2318-2330, 2019
532019
Notch pathway activation is essential for maintenance of stem-like cells in early tongue cancer
P Upadhyay, S Nair, E Kaur, J Aich, P Dani, V Sethunath, N Gardi, ...
Oncotarget 7 (31), 50437, 2016
452016
Drug-sensitiveFGFR3 mutations in lung adenocarcinoma
P Chandrani, K Prabhash, R Prasad, V Sethunath, M Ranjan, P Iyer, ...
Annals of oncology 28 (3), 597-603, 2017
422017
Evaluation of the predictive role of tumor immune infiltrate in patients with HER2-positive breast cancer treated with neoadjuvant anti-HER2 therapy without chemotherapy
C De Angelis, C Nagi, CC Hoyt, L Liu, K Roman, C Wang, Y Zheng, ...
Clinical Cancer Research 26 (3), 738-745, 2020
412020
GPCRs profiling and identification of GPR110 as a potential new target in HER2+ breast cancer
RR Bhat, P Yadav, D Sahay, DK Bhargava, CJ Creighton, S Yazdanfard, ...
Breast cancer research and treatment 170, 279-292, 2018
232018
A genome-scale CRISPR screen reveals PRMT1 as a critical regulator of androgen receptor signaling in prostate cancer
S Tang, V Sethunath, NY Metaferia, MF Nogueira, DS Gallant, ER Garner, ...
Cell reports 38 (8), 2022
212022
HER2 L755S mutation is associated with acquired resistance to lapatinib and neratinib, and confers cross-resistance to tucatinib in HER2-positive breast cancer models
J Veeraraghavan, R Mistry, S Nanda, V Sethunath, M Shea, T Mitchell, ...
Cancer Research 80 (16_Supplement), 1911-1911, 2020
102020
Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models
J Veeraraghavan, C Gutierrez, V Sethunath, S Mehravaran, M Giuliano, ...
NPJ Breast Cancer 7 (1), 63, 2021
52021
Abstract PD3-09: HER2 L755S mutation is acquired upon resistance to lapatinib and neratinib and confers cross-resistance to tucatinib and trastuzumab in HER2 …
J Veeraraghavan, R Mistry, S Nanda, V Sethunath, M Shea, T Mitchell, ...
Cancer Research 81 (4_Supplement), PD3-09-PD3-09, 2021
32021
Abstract GS2-01: High levels of interferon-response gene signatures are associated with de novo and acquired resistance to CDK4/6 inhibitors in ER+ breast cancer
C De Angelis, X Fu, ML Cataldo, A Nardone, VM Jansen, ...
Cancer Research 80 (4_Supplement), GS2-01-GS2-01, 2020
32020
Acquired neratinib resistance is associated with acquisition of HER2 and PIK3CA mutations and can be overcome using potent drug combinations in HER2 …
J Veeraraghavan, R Mistry, S Nanda, S Bose, CC Liu, V Sethunath, ...
Cancer Research 81 (13_Supplement), 1077-1077, 2021
12021
High levels of interferon-response gene signatures are associated with de novo and acquired resistance to CDK4/6 inhibitors in ER plus breast cancer
C De Angelis, X Fu, ML Cataldo, A Nardone, VM Jansen, ...
CANCER RESEARCH 80 (4), 2020
12020
Pro-oncogenic role of NOTCH1 in early tongue squamous cell carcinoma
P Upadhyay, J Aich, V Sethunath, P Dani, S Kannan, P Chandrani, ...
Cancer Research 75 (15_Supplement), 4811-4811, 2015
12015
High FOXA1 levels induce ER transcriptional reprogramming, a pro-metastatic secretome, and metastasis in endocrine-resistant breast cancer
X Fu, R Pereira, CC Liu, C De Angelis, MJ Shea, S Nanda, L Qin, ...
Cell Reports 42 (8), 2023
2023
Effect of mevalonate pathway inhibitors on outcomes of patients (pts) with HER2-positive early breast cancer (BC) in the ALTTO trial.
C De Angelis, J Veeraraghavan, V Sethunath, L Ameye, M Paesmans, ...
Journal of Clinical Oncology 40 (16_suppl), 522-522, 2022
2022
The system can't perform the operation now. Try again later.
Articles 1–20